Psy­che­delics start­up nets more than $10M in seed fund­ing as it looks to make a splash

As com­pa­nies small and large be­gin to test the wa­ters and go main­stream with a se­ries of dif­fer­ent psy­che­delics, one start­up is hop­ing to use an ex­pert in the field to ad­vance a ther­a­py us­ing ke­t­a­mine for ma­jor de­pres­sive dis­or­der.

Free­dom Bio­sciences, a clin­i­cal-stage com­pa­ny de­vel­op­ing ther­a­peu­tics us­ing ke­t­a­mine and oth­er psy­che­delics, has net­ted it­self $10.5 mil­lion in seed fi­nanc­ing.

The com­pa­ny was found­ed last April by John Krys­tal, the chair of the De­part­ment of Psy­chi­a­try at Yale Uni­ver­si­ty, and Di­na Burk­it­baye­va, co-founder of PsyMed Ven­tures. Burk­it­baye­va now serves as the start­up’s CEO, while Krys­tal serves as chief sci­en­tif­ic ad­vi­sor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER